Sugi Predict

Sugi Predict / Compounds / SCHEMBL1760875

SCHEMBL1760875

SCHEMBL1760875

CSc1nc(Cl)c([N+](=O)[O-])c(Cl)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ GABBR2 O75899 1/20 0.46
▸ GABBR1 Q9UBS5 1/20 0.46
▸ TNFSF10 P50591 1/20 0.39
▸ HASPIN Q8TF76 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ CA1 P00915 3/20 0.33
▸ CA2 P00918 3/20 0.33
▸ CA7 P43166 3/20 0.33
▸ TLR7 Q9NYK1 1/20 0.32
▸ CA13 Q8N1Q1 2/20 0.31
▸ MAPT P10636 2/20 0.30
▸ LMNA P02545 1/20 0.30
▸ HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8079399 0.89 KMT2A (0.42) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL2459755 0.87 KMT2A (0.41) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL16182530 0.87 KMT2A (0.41) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL8123964 0.86 MEN1 (0.40) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL1760966 0.84 MAPT (0.39) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL5418906 0.84 MEN1 (0.49) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL11859901 0.84 MEN1 (0.39) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL14788098 0.83 MEN1 (0.38) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL11826745 0.81 L3MBTL1 (0.42) KMT2ATDP1CYP1A2CYP2C9CYP2C19
SCHEMBL11677310 0.81 MEN1 (0.49) KMT2ATDP1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372605-B Synthesis method of 2-methylthio-4, 6-dichloro-5-nitropyrimidine 南京普锐达医药科技有限公司 2022-05-13 — — CN claimed
US-20250333418-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK AS (DK) 2025-10-30 — — US disclosed
EP-4634186-A1 2,6,9-TRISUBSTITUTED PURINES Astrazeneca AB (SE) 2025-10-22 — — EP disclosed
US-12441744-B2 2,6,9-trisubstituted purines ASTRAZENECA AB 2025-10-14 — — US disclosed
EP-4608835-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2025-09-03 — — EP disclosed
US-20250197425-A1 2,6,9-TRISUBSTITUTED PURINES ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
CN-120129684-A Purine compound, composition containing same and use thereof 诺和诺德股份有限公司 2025-06-10 — — CN disclosed
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling Université de Liège (BE) 2025-06-03 — — US disclosed
WO-2025049619-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-12110289-B2 Heterocyclic compounds, preparation methods and uses thereof InventisBio Co., Ltd. (CN) 2024-10-08 — — US disclosed
US-5397781-A Pyrimidine derivatives MOCHIDA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-03-14 — — US disclosed
EP-0561175-A1 Pyrimidine derivatives and pharmaceutical compostions containing them MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1993-09-22 — — EP disclosed
EP-0429149-A1 Tricyclic pteridinones and a process for their preparation BERLEX LABORATORIES, INC. (US) 1991-05-29 — — EP disclosed
EP-0084758-B1 PYRIMIDIN DERIVATIVES ACTIVE AS PARASITICIDES CIBA-GEIGY AG (CH) 1986-02-12 — — EP disclosed
EP-0084758-A1 Pyrimidin derivatives active as parasiticides CIBA-GEIGY AG (CH) 1983-08-03 — — EP disclosed
US-4055411-A 5-NITRO-PYRIMIDINES CIBA-GEIGY CORPORATION (US) 1977-10-25 — — US disclosed
US-4014677-A HERBICIDES CIBA-GEIGY CORPORATION (US) 1977-03-29 — — US disclosed
US-3975384-A ANTITHROMBOTICS BOEHRINGER INGELHEIM GMBH (DT) 1976-08-17 — — US disclosed
US-3969101-A 4,6-DIAMINO-5-NITRO-2-ALKYLTHIO-PYRIMIDINES CIBA-GEIGY CORPORATION (US) 1976-07-13 — — US disclosed
US-3948914-A PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1976-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12110289-B2 Heterocyclic compounds, preparation methods and uses thereof KRAS, NRAS, HRAS KMT2A 1524/4885TDP1 4651/4885CYP1A2 2929/4885
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling PIGS, TYMP, TYMS KMT2A 4361/4885TDP1 1228/4885CYP1A2 2875/4885
US-20250333418-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, P2RY1 KMT2A 3780/4885TDP1 349/4885CYP1A2 1316/4885
US-12441744-B2 2,6,9-trisubstituted purines CDK2, CDK1, CCNT2 KMT2A 1317/4885TDP1 599/4885CYP1A2 1004/4885
US-20250197425-A1 2,6,9-TRISUBSTITUTED PURINES CDK2, CDK1, CCNT2 KMT2A 1317/4885TDP1 599/4885CYP1A2 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.